IDIQ for the purchase of consumables (multi-well plates) for use in Axion Biosystems Multielectrode Array systems

The FDA Office of Acquisition and Grant Services intends to solicit an IDIQ contract for multi-well plates (12-, 48-, and 96-well configurations) compatible with Axion Biosystems Multielectrode Array systems, with capability statements due by June 3, 2026. No set-aside is anticipated. The FDA seeks small business sources capable of manufacturing newly produced plates with a minimum of 700 electrodes per plate for microphysiological studies using human induced pluripotent stem cells. Plates must support real-time well-by-well signal review, high signal quality with adjustable filters, temperature and electrical stimulation control, automatic cardiac T-wave and neural network burst identification, and measurement of field potential duration, beat period, conduction velocity, spike amplitude, viability, firing rate, and burst characteristics. Specific models required include M768-tMEA-96W (50 boxes of 5 plates, 10 boxes annually), M768-tMEA-48W (25 boxes, 5 annually), and M768-tMEA-48OPT (25 boxes, 5 annually), with quantities for additional models to be determined. The IDIQ contract covers a base year from July 31, 2026, through July 30, 2027, plus four option years. Delivery must occur within 30 days of order placement to CDER in Silver Spring, Maryland. Respondents must submit capability statements including business information, SAM Unique Entity ID, past performance data within the last three years, technical specifications, GSA Schedule or government-wide contract details if applicable, manufacturer information for resellers, warranty and payment terms, and place of manufacture information for Buy American compliance review. Email submissions to suzanne.martella@fda.hhs.gov by 3:00 pm Central Time.